Related Experiment Video
Updated: Jun 18, 2026
04:09
Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel Film
Published on: December 13, 2024
Polydiacetylene vesicles as a novel drug sustained-release system
Caixin Guo1, Shaoqin Liu, Zhifei Dai
1Instrumental Science and Technology, School Electrical Engineering and Automation, State Key Laboratory of Urban Water Resources and Environment, Harbin Institute of Technology, Harbin, China. 163gcx@sina.com
Colloids and Surfaces. B, Biointerfaces
|November 10, 2009
Summary
Novel polymerized vesicles using 10,12-pentacosadiynoic acid (PCDA) enhance drug carrier stability and control paclitaxel release. These PCDA vesicles show improved physicochemical properties compared to conventional liposomes for anticancer drug delivery.
Area of Science:
- Materials Science
- Nanotechnology
- Pharmaceutical Sciences
Background:
- Conventional liposomes face challenges in physicochemical stability and controlled drug release.
- Paclitaxel, a hydrophobic anticancer drug, requires effective delivery systems for improved therapeutic outcomes.
Purpose of the Study:
- To develop and characterize novel polymerized vesicular carriers using 10,12-pentacosadiynoic acid (PCDA) for enhanced stability and sustained release.
- To evaluate the potential of PCDA vesicles as carriers for paclitaxel, a model hydrophobic drug.
Main Methods:
- Polymerized vesicles were formulated by incorporating PCDA into lipid bilayers.
- Characterization included particle size distribution and zeta-potential measurements.
- Stability was assessed using Triton X-100, and in vitro drug release studies were conducted for paclitaxel.
Main Results:
- Polymerized PCDA vesicles exhibited tunable zeta-potential (from -3mV to over -25mV) and particle size (29nm to 149nm).
- Enhanced stability against Triton X-100 was observed compared to conventional liposomes.
- In vitro studies showed reduced paclitaxel release from PCDA vesicles (32-57% at 24h) compared to conventional liposomes (69% at 24h).
Conclusions:
- Novel polymerized PCDA vesicles offer superior physicochemical stability and sustained-release properties.
- These PCDA vesicles demonstrate significant potential as advanced drug carriers for hydrophobic anticancer agents like paclitaxel.
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...